Abstract:Gastric cancer (GC) is a common gastrointestinal malignancy, and cisplatin (DDP) is an important component of chemotherapeutic regimens for GC. However, the application of DDP is limited by its dose‑dependent systemic toxicity. Resveratrol (RES) is a natural polyphenol compound that has chemopreventive and therapeutic effects against various cancers, including GC. However, whether RES can sensitize GC cells to DDP remains unknown. Following RES/DDP combination treatment, cell viability was determined by Cell Counting Kit‑8 and colony‑forming assays, and cell apoptosis and the cell cycle were detected by FITC‑Annexin V/PI staining assay and PI staining assay, respectively, followed by flow cytometry. Moreover, western blotting was performed to evaluate the protein expression levels, and the intracellular free Ca2+ concentration was determined by a Fluo‑4 AM probe after cell cotreatment with RES and DDP. The present results demonstrated that RES/DDP combination treatment significantly inhibited cell viability, promoted cell apoptosis and induced G2/M phase arrest in AGS cells. In addition, it was determined that RES combined with DDP significantly increased the levels of Bax, cleaved poly‑ADP‑ribose polymerase (PARP), glucose‑regulated protein 78 (GRP78), PRKR‑like ER kinase (PERK), p‑eukaryotic translation initiation factor 2α (p‑eIF2α), CCAAT/enhancer binding protein homologous protein (CHOP) and cleaved caspase‑12, whereas Bcl‑2 expression was downregulated following RES/DDP cotreatment. Moreover, RES/DDP cotreatment significantly upregulated phosphorylated cyclin‑dependent kinase 1 (p‑CDK1, Tyr15), p21Waf1/Cip1 and p27Kip1 protein levels and downregulated Cdc25C protein levels. In conclusion, RES and DDP synergistically inhibited the growth of the gastric adenocarcinoma cell line AGS by inducing endoplasmic reticulum stress‑mediated apoptosis and G2/M phase arrest via activation of the PERK/eIF2α/activating transcription factor 4 (ATF4)/CHOP signaling pathway and caspase‑12 and by inactivating the CDK1‑cyclin B1 complex. These results indicated that RES is a promising adjuvant for DDP during GC chemotherapy.

Akt Inhibitor MK-2206 Enhances the Effect of Cisplatin in Gastric Cancer Cells.

MK2206 Enhances Cisplatin-Induced Cytotoxicity and Apoptosis in Testicular Cancer Through Akt Signaling Pathway Inhibition.

AKT Inhibitor MK-2206 Sensitizes Breast Cancer Cells to MLN4924, a First-in-class NEDD8-activating Enzyme (NAE) Inhibitor

Resveratrol Synergizes with Cisplatin in Antineoplastic Effects Against AGS Gastric Cancer Cells by Inducing Endoplasmic Reticulum Stress‑mediated Apoptosis and G2/M Phase Arrest.

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Akt associates with nuclear factor kappaB and plays an important role in chemoresistance of gastric cancer cells.

Overexpression of AKT decreases the chemosensitivity of gastric cancer cells to cisplatin in vitro and in vivo.

The Impact of Akt and Nuclear Factor Kb Pathway on Chemoresistance of Gastric Cancer Cell

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

RNAi Knockdown of the Akt1 Gene Increases the Chemosensitivity of Gastric Cancer Cells to Cisplatin Both in Vitro and in Vivo

Inhibition of AKT Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin by Abrogating S and G2/M Arrest.

1,25-Dihydroxyvitamin D3 and Cisplatin Synergistically Induce Apoptosis and Cell Cycle Arrest in Gastric Cancer Cells

Sequential Combination Therapy of Ovarian Cancer with Cisplatin and Γ-Secretase Inhibitor MK-0752.

Suppression of Midkine Gene Promotes the Antitumoral Effect of Cisplatin on Human Gastric Cancer Cell Line AGS in Vitro and in Vivo Via the Modulation of Notch Signaling Pathway.

The Combination of RAD001 and MK-2206 Exerts Synergistic Cytotoxic Effects Against PTEN Mutant Gastric Cancer Cells: Involvement of MAPK-dependent Autophagic, but Not Apoptotic Cell Death Pathway.

BI2536, a Potent and Selective Inhibitor of Polo-Like Kinase 1, in Combination with Cisplatin Exerts Synergistic Effects on Gastric Cancer Cells.

[6]‐Gingerol enhances the cisplatin sensitivity of gastric cancer cells through inhibition of proliferation and invasion via <scp>PI</scp>3<scp>K</scp>/<scp>AKT</scp> signaling pathway

Synergistic Antitumor Effects of Combined Deguelin and Cisplatin Treatment in Gastric Cancer Cells

Concurrent Blockade of NF-κB and Akt Pathways Potentiates Cisplatin's Antitumor Activity in Vivo.

Advanced Hierarchical Computational Modeling‐Based Rational Development of Platinum (II) Nanocomplex to Improve Lung Cancer Therapy

Proteasome Inhibitor MG132 Enhances Sensitivity to Cisplatin on Ovarian Carcinoma Cells in Vitro and in Vivo